Nandre Rahul M, Lee John Hwa
College of Veterinary Medicine, Chonbuk National University, Jeonju 561-756, South Korea.
College of Veterinary Medicine, Chonbuk National University, Jeonju 561-756, South Korea.
Vet Immunol Immunopathol. 2014 Nov 15;162(1-2):51-8. doi: 10.1016/j.vetimm.2014.08.014. Epub 2014 Sep 6.
We previously reported JOL916, a live attenuated Salmonella gallinarum (SG), as a vaccine candidate for protection from fowl typhoid (FT). In the present study, we evaluated JOL1355, an SG that secretes heat-labile enterotoxin B subunit protein, for safety, immunogenicity, and protective efficacy against FT. In a single intramuscular inoculation, live attenuated SG (JOL916) and commercial live attenuated SG9R immunized groups showed gross lesions and bacterial persistence up to 21 days post-immunization. However, the JOL1355 immunized group showed gross lesions and bacterial persistence up to only 3 and 7 days post-immunization, respectively. In addition, several birds in the JOL916 and SG9R immunized group shown clinical signs after immunization, while JOL1355 immunized birds did not show any adverse effects. In a subsequent study, birds were primed and boosted at 4 and 8 weeks of age, respectively, and compared with control birds inoculated with sterile phosphate-buffered saline. The immunized groups B (JOL916), C (SG9R), and D (JOL1355) exhibited significantly higher humoral and cellular immune responses compared to those in the unimmunized control group A. In addition, the birds of each group were challenged with virulent SG at 11 weeks of age, and significantly increased survival rates were observed in all immunized groups compared with the control group. These results indicated that JOL1355 was able to efficiently induce an acquired immune response to protect birds after challenge, and may be safer than JOL916 and the commercial vaccine SG9R in chickens.
我们之前报道了JOL916，一种减毒活鸡沙门氏菌（SG），作为预防禽伤寒（FT）的候选疫苗。在本研究中，我们评估了JOL1355，一种分泌不耐热肠毒素B亚基蛋白的SG，其安全性、免疫原性以及对FT的保护效力。在单次肌肉注射中，减毒活SG（JOL916）和市售减毒活SG9R免疫组在免疫后21天内均出现肉眼可见病变和细菌持续存在。然而，JOL1355免疫组分别在免疫后仅3天和7天出现肉眼可见病变和细菌持续存在。此外，JOL916和SG9R免疫组的几只鸡在免疫后出现临床症状，而JOL1355免疫的鸡未表现出任何不良反应。在随后的研究中，鸡分别在4周龄和8周龄时进行初次免疫和加强免疫，并与接种无菌磷酸盐缓冲盐水的对照鸡进行比较。与未免疫的对照组A相比，免疫组B（JOL916）、C（SG9R）和D（JOL1355）表现出显著更高的体液免疫和细胞免疫反应。此外，每组鸡在11周龄时用强毒SG进行攻毒，与对照组相比，所有免疫组的存活率均显著提高。这些结果表明，JOL1355能够有效诱导获得性免疫反应以在攻毒后保护鸡，并且在鸡中可能比JOL916和市售疫苗SG9R更安全。
